Diagnostic tools for diabetic sensorimotor polyneuropathy

Current Diabetes Reviews

Volumn 2, Issue 3, 2006, Pages 353-361

  Kles, Keri A ^a   Bril, Vera ^b  

^a ELI LILLY AND COMPANY   (United States)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Diabetes; Diabetic microvascular complications; Diabetic sensorimotor polyneuropathy (DPN); Diagnostic tools; Quantitative sensory testing (QST); Vibration perception threshold (VPT)

Indexed keywords

CHOLESTEROL;

AMPUTATION; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEUROPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; HEALTH CARE COST; HUMAN; MEDICAL RESEARCH; MORBIDITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYMPTOMATOLOGY; ULCER; UNITED STATES;

DIABETIC NEUROPATHIES; DIAGNOSIS, DIFFERENTIAL; HEAT; HUMANS; NEURAL CONDUCTION; SENSORY THRESHOLDS; VIBRATION;

EID: 33746927624     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339906777950598     Document Type: Review

References (110)

1. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26: 917-32.
2. Prevalence of diabetes and impaired fasting glucose in adults - United States, 1999-2000. MMWR Morb Mortal Wkly Rep 2003; 52: 833-7.
3. Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ, III, O'Brien PC. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999; 22: 1479-86.
4. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-42.
5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifictorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
6. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38: 869-80.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
8. Melton LJ, III, Dyck PJ. In Diabetic Neuropathy: Dyck PJ, Thomas PK, Asbury A, Winegard A, Porte D, Eds. Section II: epidemiology. Philadelphia, PA, WB Saunders Co 1987; 27-35.
9. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997; 49: 229-39.
10. Valensi P, Giroux C, Seeboth-Ghalayini B, Attali JR. Diabetic peripheral neuropathy: effects of age, duration of diabetes, glycemic control, and vascular factors. J Diabetes Complications 1997; 11: 27-34.
11. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia 2000; 43: 957-73.
12. Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002; 50: 325-92.
13. Kasojima H, Yamagishi S, Sugai S, Yagihashi N, Yagihashi S. Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients. Virchows Arch 2001; 439: 46-54.
14. Nishikawa T, Edelstein D, Do XL, Yamagishi S, Matsumura T, Kaneda Y et al Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
15. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004; 27: 1458-86.
16. King RH. The role of glycation in the pathogenesis of diabetic polyneuropathy. Mol Pathol 2001; 54: 400-8.
17. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23: B21-9.
18. Perkins BA, Greene DA, Bril V. Glycemic control is related to the morphological severity of diabetic sensorimotor polyneuropathy. Diabetes Care 2001; 24: 748-52.
19. Boulton AJ, Ward JD. Diabetic neuropathies and pain. Clin Endocrinol Metab 1986; 15: 917-31.
20. Boulton AJ, Pressure and the diabetic foot: clinical science and offloading techniques. Am J Surg 2004; 187: 17S-24S.
21. Boulton AJ. Lowering the risk of neuropathy, foot ulcers and amputations. Diabet Med 1998; 15: S57-9.
22. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1: 277-99.
23. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocame patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002; 18: 297-301.
24. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004; 20: 309-18.
25. Bastyr EJ, Price KL, Bril V for the MBBQ Study Group. Development and Validity Testing of the Neuropathy Total Symptom Score-6: Questionnaire for the Study of Sensory Symptoms of Diabetic Peripheral Neuropathy Clin Ther 2005; 27: 1278-1294.
26. Meijer JW, van Sonderen E, Blaauwwiekel EE, Smit AJ, Groothoff JW, Eismia WH et al. Diabetic neuropathy examination: a hierarchical scoring system to diagnose distal polyneuropathy in diabetes. Diabetes Care 2000; 23: 750-3.
27. Burns TM, Taly A, O'Brien PC, Dyck PJ. Clinical versus quantitative vibration assessment: improving clinical performance. J Peripher Nerv Syst 2002; 7: 112-7.
28. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002; 25: 2048-52.
29. Comblath DR, Chaudbry V, Carter Y, Lee D, Seysedadr M, Miernicki M et al. Total neuropathy score: validation and reliability study. Neurology 1999; 53: 1660-4.
30. Rahman M, Griffin SJ, Rathmann W, Wareham NJ. How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-based comparison of four measures. Diabet Med 2003; 20: 368-74.
31. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJ. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998; 21: 1071-5.
32. Olaleye D, Perkins BA, Bril V. Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetes Res Clin Pract 2001; 54: 115-28.
33. Hilz MJ, Axelrod FB, Hermann Y, Haertl U, Duetsch M, Neundorfer B. Normative values of vibratory perception in 530 children, juveniles and adults aged 3-79 years. J Neurol Sci 1998; 159: 219-25.
34. Kastenbauer T, Sauseng S, Brath H, Abrahamian H, Irsigler K. The value of the Rydel-Seiffer tuning fork as a predictor of diabetic polyneuropathy compared with a neurothesiometer. Diabet Med 2004; 21: 563-7.
35. Booth J, Young MJ. Differences in the performance of commercially available 10-g monofilaments. Diabetes Care 2000; 23: 984-8.
36. Yong R, Karas TJ, Smith KD, Petrov O. The durability of the Semmes-Weinstein 5.07 monofilament J Foot Ankle Surg 2000; 39: 34-8.
37. Olmos PR, Cataland S, O'Dorisio TM, Casey CA, Smead WL, Simon SR. The Semmes-Weinstein monofilament as a potential predictor of foot ulceration in patients with noninsulin-dependent diabetes. Am J Med Sci 1995; 309: 76-82.
38. Frykberg RG, Lavery LA, Pham H, Harvey C, Harkless L, Veves A. Role of neuropathy and high foot pressures in diabetic foot ulceration. Diabetes Care 1998; 21: 1714-19.
39. Pham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care 2000; 23: 606-11.
40. Kumar S, Fernando DJ, Veves A, Knowles EA, Young MJ, Boulton AJ. Semmes-Weinstein monofilaments: a simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration. Diabetes Res Clin Pract 1991; 13: 63-7.
41. Mayfield JA, Sugarman JR. The use of the Semmes-Weinstein monofilament and other threshold tests for preventing foot ulceration and amputation in persons with diabetes. J Fam Pract 2000; 49: S17-S29.
42. Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001; 24: 250-56.
43. Donofrio PD, Albers JW. AAEM minimonograph #34: polyneuropathy: classification by nerve conduction studies and electromyography. Muscle Nerve 1990; 13: 889-903.
44. Albers JW, Brown MB, Sima AA, Greene DA. Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial: the effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Tolrestat Study Group for the Early Diabetes Intervention Trial. Neurology 1996; 46: 85-91.
45. Bril V, Werb MR, Greene DA, Sima AA. Single-fibre electromyography in diabetic peripheral polyneuropathy. Muscle Nerve 1996; 19: 2-9.
46. Buchthal F. An introduction to electromyography. Copenhagen: Scandinavian University Books, Co. 1957; 1-22.
47. Perkins BA, Bril V. Diabetic neuropathy: a review emphasizing diagnostic methods. Clin Neurophysiol 2003; 114: 1167-75.
48. Perkins BA, Bril V. Diagnosis and management of diabetic neuropathy. Curr Dish Rep 2002; 2: 495-500.
49. Tkac I, Bril V. Glycemic control is related to the electrophysiologic severity of diabetic peripheral sensorimotor polyneuropathy. Diabetes Care 1998; 21: 1749-52.
50. Bril V, Ellison R, Ngo M, Bergstrom B, Raynard D, Gin H. Electrophysiological monitoring in clinical trials. Roche Neuropathy Study Group. Muscle Nerve 1998; 21: 1368-73.
51. Mackel R, Brink E. Conduction of neural impulses in diabetic neuropathy. Clin Neurophysiol 2003; 114: 248-55.
52. Perkins BA, Olaleye D, Bril V. Carpal tunnel syndrome in patients with diabetic polyneuropathy. Diabetes Care 2002; 25: 565-9.
53. Valk GD, Grootenhuis PA, van Eijk JT, Bouter LM, Bertelsmann FW. Methods for assessing diabetic polyneuropathy: validity and reproducibility of the measurement of sensory symptom severity and nerve function tests. Diabetes Res Clin Pract 2000; 47: 87-95.
54. Young RJ, Zhou YQ, Rodriguez E, Prescott RJ, Ewing DJ, Clarke BF. Variable relationship between peripheral somatic and autonomic neuropathy in patients with different syndromes of diabetic polyneuropathy. Diabetes 1986; 35: 192-7.
55. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 89-94.
56. Singleton M Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001; 24: 1448-53.
57. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 1995; 45: 1115-21.
58. Andersen H, Stalberg E, Falck B. F-wave latency, the most sensitive nerve conduction parameter in patients with diabetes mellitus. Muscle Nerve 1997; 20: 1296-1302.
59. Shin JB, Seong YJ, Lee HJ, Kim SH, Suk H, Lee YJ. The usefulness of minimal F-wave latency and sural/radial amplitude ratio in diabetic polyneuropathy. Yonsei Med J 2000; 41: 393-7.
60. Rutkove SB, Kothari MJ, Raynor EM, Levy ML, Fadic R, Nardin RA. Sural/ radial amplitude ratio in the diagnosis of mild axonal polyneuropathy. Muscle Nerve 1997; 20: 1236-41.
61. Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care 1988; 11: 592-7.
62. Peripheral Nerve Society. Diabetic polyneuropathy in controlled clinical trials: Consensus Report of the Peripheral Nerve Society. Ann Neurol 1995; 38: 478-82.
63. Arezzo JC, Zotova E. Electrophysiologic measures of diabetic neuropathy: mechanism and meaning. Int Rev Neurobiol 2002; 50: 229-55.
64. Padua L, Saponara C, Ghirlanda G, Padua R, Aprile I, Caliandro P et al. Lower limb nerve impairment in diabetic patients: multiperspective assessment. Eur J Neurol 2002; 9: 69-73.
65. Airey M, Bennett C, Nicolucci A, Williams R. Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev 2000: CD002182.
66. Muller-Felber W, Landgraf R, Scheuer R, Wagner S, Reimers CD, Nusser J et al. Diabetic neuropathy 3 years after successful pancreas and kidney transplantation. Diabetes 1993; 42: 1482-6.
67. Kohara N, Kimura J, Kaji R, Goto Y, Ishii J, Takiguchi M et aL F-wave latency serves as the most reproducible measure in nerve conduction studies of diabetic polyneuropathy: multicentre analysis in healthy subjects and patients with diabetic polyneuropathy. Diabetologia 2000; 43: 915-21.
68. Veves A, Malik RA, Lye RH, Masson EA, Sharma AK, Schady W et al. The relationship between sural nerve morphometric findings and measures of peripheral nerve function in mild diabetic neuropathy. Diabet Med 1991; 8: 917-21.
69. Russell JW, Karnes JL, Dyck PJ. Sural nerve myelinated fibre density differences associated with meaningful changes in clinical and electrophysiologic measurements. J Neurol Sci 1996; 135: 114-7.
70. Yang Q, Kaji R, Takagi T, Kohara N, Murase N, Yamada Y et al. Abnormal axonal inward rectifier in streptozocin-induced experimental diabetic neuropathy. Brain 2001; 124: 1149-55.
71. Burke D, Kiernan MC, Bostock H. Excitability of human axons. Clin Neurophysiol 2001; 112: 1575-85.
72. Kiernan MC, Lin CS, Andersen KV, Murray NM, Bostock H. Clinical evaluation of excitability measures in sensory nerve. Muscle Nerve 2001; 24: 883-92.
73. Bril V, Kojic J, Ngo M, Clark K. Comparison of a neurothesiometer and vibration in measuring vibration perception thresholds and relationship to nerve conduction studies. Diabetes Care 1997; 20: 1360-2.
74. Horowitz SH. Correlation of near-nerve sural conduction and quantified sensory testing in patients with diabetic neuropathy. Muscle Nerve 1995; 18: 1202-4.
75. Feki I, Lefaucheur JP. Correlation between nerve conduction studies and clinical scores in diabetic neuropathy. Muscle Nerve 2001; 24: 555-8.
76. Shy ME, Frohman EM, So YT, Arezzo JC, Comblath DR, Giuliani MJ et al. Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 60: 898-904.
77. Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindstrom P, Wahren J. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes 2003; 52: 536-41.
78. Coppini DV, Wellmer A, Weng C, Young PJ, Anand P, Sonksen PH. The natural history of diabetic peripheral neuropathy determined by a 12 year prospective study using vibration perception thresholds. J Clin Neurosci 2001; 8: 520-4.
79. Gerr F, Letz R. Covariates of human peripheral nerve function: II. Vibrotactile and thermal thresholds. Neurotoxicol Teratol 1994; 16: 105-12.
80. Gelber DA, Pfeifer MA, Broadstone VL, Munster EW, Peterson M, Arezzo JC et al. Components of variance for vibratory and thermal threshold testing in normal and diabetic subjects. J Diabetes Complications 1995; 9: 170-6.
81. Dyck PJ, Dyck PJ, Kennedy WR, Kesserwani H, Melanson M, Ochoa J et al. Limitations of quantitative sensory testing when patients are biased toward a bad outcome. Neurology 1998; 50: 1213.
82. Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 1994; 17: 557-60.
83. Kastenbauer T, Sauseng S, Sokol G, Auinger M, Irsigler K. A prospective study of predictors for foot ulceration in type 2 diabetes. J Am Podiatr Med Assoc 2001; 91: 343-50.
84. Chong PS, Cros DP. Technology literature review: quantitative sensory testing. Muscle Nerve 2004; 29: 734-47.
85. Bril V, Perkins BA. Comparison of vibration perception thresholds obtained with the Neurothesiometer and the CASE IV and relationship to nerve conduction studies. Diabet Med 2002; 19: 661-6.
86. Ziegler D, Mayer P, Gries FA. Evaluation of thermal, pain, and vibration sensation thresholds in newly diagnosed type 1 diabetic patients. J Neurol Neurosurg Psychiatry 1988; 51: 1420-4.
87. Dyck PJ, Dyck PJ, Larson TS, O'Brien PC, Velosa JA, Nerve growth factor study group. Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Diabetes Care 2000; 23: 510-7.
88. Boulton AJ, Kubrusly DB, Bowker JH, Gadia MT, Quintero L, Becker DM et al. Impaired vibratory perception and diabetic foot ulceration. Diabet Med 1986; 3: 335-7.
89. Maser RE, Laudadio C, Lenhard MJ, DeCherney GS. A cross-sectional study comparing two quantitative sensory testing devices in individuals with diabetes. Diabetes Care 1997; 20: 179-81.
90. Zinman LH, Bril V, Perkins BA. Cooling Detection Thresholds in the Assessment of Diabetic Sensory Polyneuropathy: Comparison of CASE IV and Medoc instruments. Diabetes Care 2004; 27: 1674-9.
91. Abad F, Diaz-Gomez NM, Rodriguez I, Perez R, Delgado JA. Subclinical pain and thermal sensory dysfimction in children and adolescents with Type 1 diabetes mellitus. Diabet Med 2002; 19: 827-31.
92. Yarnitsky D, Sprecher E, Zaslansky R, Hemli JA. Heat pain thresholds: normative data and repeatability. Pain 1995; 60: 329-32.
93. Arezzo JC. New developments in the diagnosis of diabetic neuropathy. Am J Med 1999; 107: 9S-16S.
94. Park R, Wallace MS, Schulteis G. Relative sensitivity to alfentanil and reliability of current perception threshold vs von Frey tactile stimulation and thermal sensory testing. J Peripher Nerv Syst 2001; 6:232-40.
95. Navarro Y, Kennedy WR. Evaluation of thermal and pain sensitivity in type I diabetic patients. J Neurol Neurosurg Psychiatry 1991; 54: 60-4.
96. Sima AA, Brown MB, Prashar A, Chakrabard S, Laudadio C, Greene DA. The reproducibility and sensitivity of sural nerve morphometry in the assessment of diabetic peripheral polyneuropathy. Diabetologia 1992; 35 (6): 560-9.
97. Sima AA. Diabetic neuropathy - the utility of nerve biopsy. Electroencephalogr Clin Neurophysiol Suppl 1999; 50:525-33.
98. Dahlin LB, Eriksson KF, Sundkvist G. Persistent postoperative complaints after whole sural nerve biopsies in diabetic and non-diabetic subjects. Diabet Med 1997; 14: 353-6.
99. Perry JR, Bril V. Complications of sural nerve biopsy in diabetic versus non-diabetic patients. Can J Neurol Sci 1994; 21: 34-7.
100. Greene DA, Brown MB. Validation of sural nerve fibre density and percent normal teased fibres as morphological endpoints in clinical trials of diabetic neuropathy. In: Hotta N, Greene DA, Ward JD, Sims. AA, Boulton AJ, editors. Diabetic Nearopathy: New Concepts and Insights. Amsterdam: Elsevier, 1995: 379-85.
101. Said G, Goulon-Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 1994; 35: 559-69.
102. Hirai A, Yasuda H, Joko M, Maeda T, Kikkawa R. Evaluation of diabetic neuropathy through the quantitation of cutaneous nerves. J Neurol Sci 2000; 172: 55-62.
103. Polydefkis M, Hauer P, Griffin JW, McArthur JC. Skin biopsy as a tool to assess distal small fibre innervation in diabetic neuropathy. Diabetes Technol Ther 2001; 3: 23-8.
104. Lindberger M, Schroder HD, Schultzberg M, Kristensson K, Persson A, Ostman J et al. Nerve fibre studies in skin biopsies in peripheral neuropathies. I. Immunohistochemical analysis of neuropeptides in diabetes mellitus. J Neurol Sci 1989; 93: 289-96.
105. Levy DM, Terenghi G, Go XH, Abraham RR, Springall DR, Polak JM. Immunohistochemical. measurements of nerves and neuropeptides in diabetic skin: relationship to tests of neurological function. Diabetologia 1992; 35: 889-97.
106. Periquet MI, Novak V, Collins MP, Nagarija HN, Erdem S, Nash SM et al. Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology 1999; 53: 1641-7.
107. McArthur JC, Stocks EA, Hauer P, Comblath DR, Griffin JW. Epidermal nerve fibre density: normative reference range and diagnostic efficiency. Arch Neurol 1998; 55: 1513-20.
108. Eaton SE, Harris ND, Rajbhandari SM, Greenwood P, Wilkinson ID, Ward JD et al. Spinal-cord involvement in diabetic peripheral neuropathy. Lancet 2001; 358: 35-6.
109. Vileikyte L, Rubin RR, Leventhal H. Psychological aspects of diabetic neuropathic foot complications: an overview. Diabetes Metab Res Rev 2004; 20: S13-S18.
110. Vileikyte L, Peyrot M, Bundy C, Rubin RR, Leventhal H, Mora P et al. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care 2003; 26: 2549-55.